Format

Send to

Choose Destination
J Enzyme Inhib Med Chem. 2014 Aug;29(4):469-75. doi: 10.3109/14756366.2013.804072. Epub 2013 Aug 5.

Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: solution and in silico studies.

Author information

1
University of Calgary, Institute for Biocomplexity and Informatics , Calgary, AB , Canada .

Abstract

Grayanotoxin III (GTX3) was investigated for inhibition of all catalytically active mammalian carbonic anhydrase (CA, EC 4.2.1.1) isoforms, i.e. CA I to CA XIV. It showed micromolar inhibition (KIs of 8.01 and 6.13 µM) for cytosolic isoforms CA I and II, respectively. GTX3 showed a submicromolar inhibition (KIs in the range of 0.51-2.15 µM) for the remaining cytosolic (CA III, VII and XIII), membrane-associated/transmembrane (CA IV, IX, XII and XIV), mitochondrial (CA VA and CA VB) and secreted (CA VI) isoforms. This inhibition profile is very different from that of the sulfonamide CA inhibitors (CAIs), which possess different clinical applications. A molecular docking study for GTX3 within the active sites of CA I and II assisted to the understanding of molecular mechanism of the ligand. The interesting inhibition profile, coupled with various possibilities of interacting with the enzyme active site make this family of natural compounds attractive leads for designing novel chemotypes acting as CAIs.

KEYWORDS:

Carbonic anhydrase; grayanotoxin III; molecular docking

PMID:
23914927
DOI:
10.3109/14756366.2013.804072
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center